These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

8872 related items for PubMed ID: 1695048

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. [Serum interferon level and (2'-5')-oligo(A) synthetase activity in pityriasis rosea, basalioma, melanoma and molluscum contagiosum].
    Lang MH, Lodemann E, Holzmann H, Heimbrodt M.
    Z Hautkr; 1988 Dec 15; 63(12):1028-36. PubMed ID: 2464248
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Induction of 2'-5' oligoadenylate synthetase during interferon treatment of chronic myelogenous leukemia.
    Moritz T, Weissmann B, Grünewald B, Hust H, Kummer G, Niederle N.
    Mol Biother; 1992 Jun 15; 4(2):97-102. PubMed ID: 1381190
    [Abstract] [Full Text] [Related]

  • 5. Increased 2',5'-oligoadenylate synthetase activity in blood mononuclear leukocytes from patients with advanced cutaneous T-cell lymphoma.
    Vonderheid EC, Suhadolnik RJ, Sobel EL, Flick MB, Mosca JD.
    Clin Immunol Immunopathol; 1984 Apr 15; 31(1):138-50. PubMed ID: 6199147
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [The effect of different types of recombinant interferon on the induction of 2,5-oligoadenylate synthetase in natural killers and the tumor cells in bladder cancer patients].
    Vozianov AF, Drannik GN, Verkhatskaia AA, Zavelevich MP, Prokhnevskaia EL, Verkhatskiĭ PP, Klimenko IA.
    Urol Nefrol (Mosk); 1993 Apr 15; (5):22-5. PubMed ID: 7508649
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Serum levels of 2',5 oligoadenylate synthetase during interferon therapy in patients with B-cell chronic lymphocytic leukemia.
    Musolino C, Grosso P, Alonci A, Allegra A, Orlando A, Cincotta M, Buda G, Squadrito G.
    Am J Hematol; 1993 May 15; 43(1):1-4. PubMed ID: 8317456
    [Abstract] [Full Text] [Related]

  • 12. Monitoring of interferon treatment in patients with renal cell carcinoma and bladder carcinoma by oligo-A synthetase assay and determination of immunological parameters.
    Grups JW, Komprecht B.
    J Biol Regul Homeost Agents; 1989 May 15; 3(3):98-101. PubMed ID: 2516404
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Interferon and 2-5A synthetase in patients with immune diseases.
    Preble OT, Yeh TJ, Silverman RH, Klippel JH, Straus SE, Gelmann EP.
    Prog Clin Biol Res; 1985 May 15; 202():415-22. PubMed ID: 2421319
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. High level activity of 2', 5'-oligoadenylate synthetase in dog serum.
    Iwata A, Yamamoto A, Fujino M, Sato I, Hosokawa-Kanai T, Tuchiya K, Ishihama A, Sokawa Y.
    J Vet Med Sci; 2004 Jun 15; 66(6):721-4. PubMed ID: 15240951
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 444.